论文

论文发表

    1. Yahui Liu, Yanan Quan, Qi Mao, Ruolin Xu, and Wanyi Tai*. “Exploring the potentials of antibody-siRNA conjugates in tumor cell gene silencing without cationic assistance” Bioconjugate. Chem., 2025, in revision. doi: https://doi.org/10.1021/ [PDF]
    2. Shiwei Song, Weina Jing, Lei Peng, Jiaqi Liu, and Wanyi Tai*. “Small molecule-degrader conjugates: studying structure-activity relationship of linkers to overcome in-vivo barriers in PROTAC delivery” J. Med. Chem., 2025, in revision. doi: https://doi.org/10.1021/ [PDF]
    3. Shiwei Song, Yahui Liu, Jiaqi Liu, and Wanyi Tai*. “In silico-driven THIOMAB approach for stable PROTAC conjugates by docking payloads in antibody cavities” Bioconjugate Chem., 2025, epub. doi: https://doi.org/10.1021/acs.bioconjchem.4c00588 [PDF]
    4. Yan Zheng#, Hong Cheng#, Sibo Jiang, and Wanyi Tai*. “Fc multisite conjugation and prolonged delivery of the folate-targeted drug conjugate EC140.” Bioconjugate Chem., 2025, 36(4), 762–769. doi: https://doi.org/10.1021/acs.bioconjchem.5c00037 [PDF]
    5. Weina Jing, Lei Peng, Shiwei Song, Jiaqi Liu, and Wanyi Tai*. “A new protractor potentiates Glucagon-like peptide 1 with slow-release depot and long-term action.” J. Med. Chem., 2025, 68(7), 7341–7352. doi: https://doi.org/10.1021/acs.jmedchem.4c02970 [PDF]
    6. Shiwei Song, Wanrong Yang, Wanyi Tai*. “Proteolysis targeting chimera of BI-2536 induces potent dual degradation of PLK1 and BET proteins.” Bioorg. Med. Chem., 2025, 120:118087. doi: https://doi.org/10.1016/j.bmc.2025.118087 [PDF]
    7. Yahui Liu, Yuelei Ling and Wanyi Tai*. “Mechanical extrusion of plasma membrane to generate ectosome-mimetic nanovesicles for the lung targeting.” Mol. Pharmaceutics, 2025, 22, 1, 304–315. doi: https://doi.org/10.1021/acs.molpharmaceut.4c00927 [PDF]
    8. Hao Wang, Jiajie Song, Yanan Quan, Jiaqi Liu and Wanyi Tai*. “Chemically programmed Fc protein as antibody mimetic to targeting carbonic anhydrase IX.” Bioconjugate Chem. 2024, 35(10), 1459–1467. doi: https://doi.org/10.1021/acs.bioconjchem.4c00259 [PDF]
    9. Siyi Chen, Qi Mao, Hong Cheng*, and Wanyi Tai*. “RNA-binding small molecules in drug discovery and delivery: an overview from fundamentals.” J. Med. Chem. 2024, 67(18), 16002–16017. doi: https://doi.org/10.1021/acs.jmedchem.4c01330 [PDF]
    10. Ruolin Xu , Yan Zheng , Wanyi Tai*. “A single-chain Fab derived drug conjugate for HER2 specific delivery.” Biomaterials 2024, 313, 122798. doi: https://doi.org/10.1016/j.biomaterials.2024.122798 [PDF]
    11. Yan Zheng, Ruolin Xu, Hong Cheng, Wanyi Tai*. “Mono-amino acid linkers enable highly potent small molecule-drug conjugates by conditional release.” Mol. Ther. 2024, 32(4):1048-1060. doi: https://doi.org/10.1016/j.ymthe.2024.02.020 [PDF]
    12. Shaowei Sui, Hao Wang, Jiajie Song, Wanyi Tai*. “Development of a spermine lipid for transient antibody expression.” Bioorg. Med. Chem. 2023, 78, 117114. doi: https://doi.org/10.1016/j.bmc.2022.117114 [PDF]
    13. Yan Zheng, Ruolin Xu, Siyi Chen, Wanyi Tai*. “In vivo therapeutic effects of small molecule-drug conjugates enhanced by Fc grafting.” Biomaterials. 2022, 290, 121820. doi: https://doi.org/10.1016/j.biomaterials.2022.121820 [PDF]
    14. Wen Wang, Wanyi Tai*. “RNA binding protein as monodisperse carriers for siRNA delivery.” Med. Drug Discov. 2019, 3, 100011. doi: https://doi.org/10.1016/j.medidd.2019.100011 [PDF]
    15. Yan Zheng, Wanyi Tai*. “Insight into the siRNA transmembrane delivery — from cholesterol conjugating to tagging.” WIREs Nanomed. Nanobiotechnol. 2019, e1606. doi: https://doi.org/10.1002/wnan.1606 [PDF]
    16. Wanyi Tai*. “Current aspects of siRNA bioconjugate for in vitro and in vivo delivery.” Molecules 2019, 24(12), 2211. doi: https://doi.org/10.3390/molecules24122211 [PDF]
    17. Wanyi Tai*. “Chemical Modulation of siRNA lipophilicity for efficient delivery.” J. Control. Release 2019, 307, 98-107. doi: https://doi.org/10.1016/j.jconrel.2019.06.022 [PDF]

Prior to joining WHU

  1. Wanyi Tai#, Pengfei Zhao#, Xiaohu Gao*. “Cytosolic delivery of proteins by cholesterol tagging.” Sci. Adv. 2020, 6, abb0310. doi: https://doi.org/10.1126/sciadv.abb0310
  2. Wanyi Tai, Xiaohu Gao*. “Silencing ribonucleoprotein: a biomimetic platform for targeted siRNA delivery.” Adv. Funct. Mater. 2019, 29, 1902221. doi: https://doi.org/10.1002/adfm.201902221
  3. Wanyi Tai, Xiaohu Gao*. “Synthetic polymer tag for intracellular delivery of siRNA.” Adv. Biosyst. 2018, 2. 1800075. doi: https://doi.org/10.1002/adbi.201800075
  4. Wanyi Tai, Junwei Li, Eva Corey, Xiaohu Gao*. “A ribonucleoprotein octamer for targeted siRNA delivery.” Nat. Biomed. Eng. 2018, 2(5), 326-337. doi: https://doi.org/10.1038/s41551-018-0214-1
  5. Wanyi Tai, Xiaohu Gao*. “Noncovalent tagging of siRNA with steroids for transmembrane delivery.” Biomaterials 2018, 178. 720-727. doi: https://doi.org/10.1016/j.biomaterials.2018.02.007
  6. Wanyi Tai, Xiaohu Gao*. “Functional peptides for siRNA delivery.” Adv. Drug Deliv. Rev. 2017, 110–111, 157–168. doi: https://doi.org/10.1016/j.addr.2016.08.004
  7. Wanyi Tai, Ran Mo, Jin Di, Vinayak Subramanian, Xiao Gu, Zhen Gu*. “Bio-inspired nanovesicles for glucose-responsive release of insulin.” Biomacromolecules 2014, 15(10), 3495-3502. doi: https://doi.org/10.1021/bm500364a
  8. Wanyi Tai#, Ran Mo#, Yue Lu, Tianyue Jiang, Zhen Gu*. “Folding graft copolymer with pendant drug segment for co-delivery of anticancer drugs.” Biomaterials 2014, 35(25), 7194-7203. doi: https://doi.org/10.1016/j.biomaterials.2014.05.004
  9. Wanyi Tai, Zhijin Chen, Ashutosh Barve, Zhonghua Peng, Kun Cheng*. “A novel rapamycin-polymer conjugate based on a new poly(ethylene glycol) multiblock copolymer.” Pharm. Res. 2014, 31(3), 706-719. doi: https://doi.org/10.1007/s11095-013-1192-3
  10. Wanyi Tai, Zhijin Chen, Kun Cheng*. “Expression profile and functional activity of peptide transporters in prostate cancer cells.” Mol. Pharmaceutics, 2013, 10(2), 477-487. doi: https://doi.org/10.1021/mp300364k
  11. Wanyi Tai, Ravi S. Shukla, Bin Qin, Benyi Li, Kun Cheng*. “Development of a peptide-drug conjugate for prostate cancer therapy.” Mol. Pharmaceutics, 2011, 8(3), 901-912. doi: https://doi.org/10.1021/mp200007b
  12. Wan-Yi Tai#, Run-Tao Zhang#, Yi-Ming Ma, Min Gu, Gang Liu, Jia Li, Fa-Jun Nan*. “Design, synthesis, and biological evaluation of ring‐opened bengamide analogues.” ChemMedChem 2011, 6(9), 1555-1558. doi: https://doi.org/10.1002/cmdc.201100164
  13. Wanyi Tai, Rubi Mahato, Kun Cheng*. “The role of HER2 in cancer therapy and targeted drug delivery.” J. Control. Release 2010, 146(3), 264-275. doi: https://doi.org/10.1016/j.jconrel.2010.04.009
  14. Wanyi Tai, Bin Qin, Kun Cheng*. “Inhibition of breast cancer cell growth and invasiveness by dual silencing of HER-2 and VEGF.” Mol. Pharmaceutics, 2010, 7(2), 543-556. doi: https://doi.org/10.1021/mp9002514
  15. Gang Liu#, Yi-Ming Ma#, Wan-Yi Tai#, Chuan-Ming Xie, Yu-Lin Li, Jia Li and Fa-Jun Nan*. “Design, synthesis, and biological evaluation of caprolactam-modified bengamide analogues.” ChemMedChem 2008, 3(1), 74–78. doi: https://doi.org/10.1002/cmdc.200700214